The largest database of trusted experimental protocols

Viromer blue transfection reagent

Manufactured by OriGene
Sourced in United States

Viromer Blue is a transfection reagent designed for the delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into mammalian cells. It facilitates the efficient uptake and intracellular delivery of these molecules.

Automatically generated - may contain errors

2 protocols using viromer blue transfection reagent

1

AhR Signaling Regulation of c-fos and NFATc1

Check if the same lab product or an alternative is used in the 5 most similar protocols
To confirm the effect of blocking AhR signaling on regulating c-fos and NFATc1 expression, genetic knock down of AhR was performed. In Brief, Raw 264.7 cells at density of 4 × 104 cells/well were seeded in 12 well plate and allowed to attach overnight. Next day, cells were transfected using Viromer Blue transfection reagent (#TT100300, OriGene Technologies, Rockville, MD, USA) and Ahr Mouse Small interfering RNA (siRNA) Oligo Duplex (AhR si, # SR420301C, OriGene Technologies, Rockville, MD, USA) at a final concentration of 10 nM. Trilencer-27 Universal scrambled negative control siRNA duplex was used to transfect control groups at a final concentration of 10 nM. One or two days after transfection, cells were treated with KYN (10 or 25 μM) with or without RANKL (20 ng/mL) for 24 h before collecting the cells for further Western blotting analyses.
+ Open protocol
+ Expand
2

Modulating Myofibroblast Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human fibroblasts were cultured in 96-well plates. After 24 h, we differentiated fibroblasts into myofibroblasts by incubation with TGFβ for three days, with re-stimulation with TGFβ every twenty-four hours. We then treated the cells with CQ (10 µM, Biotrend) or 3-MA (5 mM, Sigma-Aldrich). Alternatively, we knocked down ATG7 and BECLIN1 (50 nM) (pre-designed, Invitrogen, CA, USA), via siRNA transfection using Viromer Blue transfection reagent (OriGene Technologies, Rockville, MD, USA), and continued the stimulation with recombinant TGFβ for two additional days. The control group (Fib) was pre-treated with vehicle for three days, then transfected with non-targeting siRNA and treated with vehicle for additional two days. The deactivated myofibroblast group (deact MyoFib) was pre-treated with TGFβ for three days, then transfected with non-targeting siRNA and treated with vehicle for two days. Afterwards, cells were fixed with 4% PFA and immunostained for stress fibers and αSMA as described above (immunohistochemistry and immunofluorescence staining section). Images were captured using CellInsight CX5 High-Content Screening (HCS) Platform (Thermo Fisher Scientific; software HCS Navigator Version 6.6.1). Data were analyzed using HCS Studio Cell Analysis Software 6.6.1 (Thermo Fisher Scientific).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!